Why the study?
Does gene therapy via exon skipping or utrophin analogue restore normal myofiber elasticity in dystrophic muscles?
Does gene therapy via exon skipping or utrophin analogue restore normal myofiber elasticity in dystrophic muscles?
Answers are grounded in this paper and cite their sources.
Gene therapy via exon skipping or utrophin analogue restores normal myofiber elasticity in dystrophic muscles, which can be quantified at single-cell resolution using atomic force microscopy.
Dystrophin mediates a physical link between the cytoskeleton of muscle fibers and the extracellular matrix, and its absence leads to muscle degeneration and dystrophy. In this article, we show that the lack of dystrophin affects the elasticity of individual fibers within muscle tissue explants, as probed using atomic force microscopy (AFM), providing a sensitive and quantitative description of the properties of normal and dystrophic myofibers. The rescue of dystrophin expression by exon skipping or by the ectopic expression of the utrophin analogue normalized the elasticity of dystrophic muscles, and these effects were commensurate to the functional recovery of whole muscle strength. However, a more homogeneous and widespread restoration of normal elasticity was obtained by the exon-skipping approach when comparing individual myofibers. AFM may thus provide a quantification of the functional benefit of gene therapies from live tissues coupled to single-cell resolution.
No takes yet. Share an insight, caveat, or question.
Puttini et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: